Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Pharmaceutical discount contract for Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
- Supply of the drug under uniform conditions set by TK
Show full summary
Open House procedure by Techniker Krankenkasse (TK) for discount contracts on the drug Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) under §130c SGB V. The procedure allows continuous joining during the contract term (max 24 months from March 2025 to February 2027). No estimated value provided; no competition or award criteria; eligibility requires being a pharmaceutical entrepreneur with authorization for the drug. Submission is by email (with qualified electronic signature) or post. Documents are available but were not analyzed.
Risks
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
- Must have a valid marketing authorization for the drug in Germany or be otherwise entitled to market it
Eligibility
- Must provide a self-declaration confirming eligibility and no exclusion grounds
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Discount contracts for the combination drug Bictegravir/Emtricitabin/Tenofoviralafenamid. Continuous enrollment; no exclusivity; standard conditions.
Location
Duration
Category
Award Criteria
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) zu schließen.
Value note
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) zu schließen.
Procurement Details
- Publication date
- 19 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 39458-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications